Bifidobacterium breve is a probiotic bacterium that has been studied for its potential to support various aspects of gastrointestinal health, including the small intestine. Scientific interest in B. breve stems from its ability to colonize the human gut, modulate the immune system, and compete with pathogenic bacteria. Several clinical and preclinical studies have shown that B. breve can help restore and maintain a balanced intestinal microbiota, which is crucial for the optimal function of the small intestine.

In particular, B. breve has demonstrated benefits in reducing symptoms of irritable bowel syndrome (IBS) and improving gut barrier integrity, both of which are related to small intestine health. A 2018 review in the journal Frontiers in Microbiology summarized evidence that B. breve supplementation can enhance mucosal immunity and inhibit the growth of harmful bacteria in the small intestine. Additionally, randomized controlled trials have reported improvements in gastrointestinal discomfort and normalization of bowel movements with B. breve use, though many studies include this strain as part of multi-strain probiotic formulations rather than as a single agent.

While more high-quality, large-scale clinical trials are needed—particularly those focusing directly on small intestine function—current evidence supports a moderate scientific basis for the use of Bifidobacterium breve in supporting small intestine health.